The authors wish to make the following corrections to this paper [1].
The authors have made a critical typing error and a counting error in Table 2 as the parameters of “Community-acquired infection” and “Healthcare-associated infection” were mistakenly switched with each other.
Table 2.
Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
| Characteristics | All (n = 92) | Number of Episodes (%) | OR (95% CI) | p-Value | |
|---|---|---|---|---|---|
|
E. meningoseptica (n = 20) |
E. anophelis (n = 72) |
||||
| Sex | |||||
| Male | 64 (69.6) | 15 (75) | 49 (68.1) | 1.41 (0.46–4.35) | 0.55 |
| Female | 28 (30.4) | 5 (25) | 23 (31.9) | 0.71 (0.23–2.19) | 0.55 |
| Age | |||||
| Range (year) | 3–89 | 18–80 | 3–89 | ||
| Median (year) | 61 | 61 | 62.5 | ||
| Mean ± standard deviation (year) | 61.1 ± 17 | 56.6 ± 15.6 | 62.4 ± 17.3 | 0.179 | |
| Comorbidity | |||||
| Diabetes mellitus | 24 (26.1) | 6 (30) | 18 (25) | 1.29 (0.43–3.84) | 0.652 |
| Hypertension | 26 (28.3) | 4 (20) | 22 (30.6) | 0.57 (0.17–1.9) | 0.354 |
| End-stage renal disease | 5 (5.4) | 1 (5) | 4 (5.6) | 0.9 (0.09–8.49) | 0.999 |
| Malignancy | 40 (43.5) | 8 (40) | 32 (44.4) | 0.83 (0.3-2.28) | 0.723 |
| Liver cirrhosis | 8 (8.7) | 3 (15) | 5 (6.9) | 2.37 (0.51–10.89) | 0.365 |
| Chronic obstructive pulmonary disease | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
| Type of infection acquisition | |||||
| Community-acquired infection | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
| Healthcare-associated infection | 83 (90.2) | 20 | 63 (87.5) | 0.197 | |
| Laboratory data | |||||
| White blood cell count (cells/mm3) | 13,281 ± 8740 | 13,353 ± 6687 | 13,261 ± 9271 | 0.967 | |
| Hemoglobin (g/dL) | 10.1 ± 2.1 | 9.8 ± 2.4 | 10.1 ± 2.1 | 0.585 | |
| Platelet count (×1000 cells/mm3) | 228,570 ± 131,056 | 216,550 ± 157,332 | 231,900 ± 123,846 | 0.69 | |
| Serum creatinine (mg/dL) | 1.8 ± 1.7 | 1.6 ± 1.3 | 1.9 ± 1.8 | 0.584 | |
| Empirical antimicrobial therapy | |||||
| β-lactams | 41 (44.6) | 11 (55) | 30 (41.7) | 1.71 (0.63–4.64) | 0.289 |
| β-lactam/lactamase inhibitors | 20 (21.7) | 4 (20) | 16 (22.2) | 0.88 (0.26–2.99) | 0.999 |
| Ciprofloxacin | 10 (10.9) | 1 (5) | 9 (12.5) | 0.37 (0.04–3.1) | 0.685 |
| Levofloxacin | 24 (26.1) | 1 (5) | 23 (31.9) | 0.11 (0.01–0.89) | 0.015 |
| Carbapenems | 17 (18.5) | 4 (20) | 13 (18.1) | 1.14 (0.33–3.96) | 0.999 |
| Aminoglycosides | 9 (9.8) | 3 (15) | 6 (8.3) | 1.94 (0.44–8.57) | 0.402 |
| Tigecycline | 8 (8.7) | 2 (10) | 6 (8.3) | 1.22 (0.23–6.58) | 0.999 |
| Colistin | 6 (6.5) | 1 (5) | 5 (6.9) | 0.71 (0.08–6.41) | 0.999 |
| Inappropriate empirical antimicrobial therapy | 74 (80.4) | 20 (100) | 54 (75) | 0.01 | |
| Shock | 42 (45.7) | 9 (45) | 33 (45.8) | 0.97 (0.36–2.62) | 0.999 |
| Admission to intensive care unit | 44 (47.8) | 9 (45) | 35 (48.6) | 0.87 (0.32–2.34) | 0.775 |
| Case fatality | 25 (27.2) | 6 (30) | 19 (26.4) | 1.2 (0.4–3.56) | 0.748 |
Abbreviations: OR, odds ratio; CI, confidence interval.
Accordingly, Table 2, which is shown as follows:
Table 2.
Demographic characteristics, clinical information, and outcome of patients with E. meningoseptica and E. anophelis infections.
| Characteristics | All (n = 92) | Number of Episodes (%) | OR (95% CI) | p-Value | |
|---|---|---|---|---|---|
|
E. meningoseptica (n = 20) |
E. anophelis (n = 72) |
||||
| Sex | |||||
| Male | 64 (69.6) | 15 (75) | 49 (68.1) | 1.41 (0.46–4.35) | 0.55 |
| Female | 28 (30.4) | 5 (25) | 23 (31.9) | 0.71 (0.23–2.19) | 0.55 |
| Age | |||||
| Range (year) | 3–89 | 18–80 | 3–89 | ||
| Median (year) | 61 | 61 | 62.5 | ||
| Mean ± standard deviation (year) | 61.1 ± 17 | 56.6 ± 15.6 | 62.4 ± 17.3 | 0.179 | |
| Comorbidity | |||||
| Diabetes mellitus | 24 (26.1) | 6 (30) | 18 (25) | 1.29 (0.43–3.84) | 0.652 |
| Hypertension | 26 (28.3) | 4 (20) | 22 (30.6) | 0.57 (0.17–1.9) | 0.354 |
| End-stage renal disease | 5 (5.4) | 1 (5) | 4 (5.6) | 0.9 (0.09–8.49) | 0.999 |
| Malignancy | 40 (43.5) | 8 (40) | 32 (44.4) | 0.83 (0.3-2.28) | 0.723 |
| Liver cirrhosis | 8 (8.7) | 3 (15) | 5 (6.9) | 2.37 (0.51–10.89) | 0.365 |
| Chronic obstructive pulmonary disease | 9 (9.8) | 0 | 9 (12.5) | 0.197 | |
| Type of infection acquisition | |||||
| Community-acquired infection | 10 (10.9) | 20 | 63 (87.5) | 0.197 | |
| Healthcare-associated infection | 82 (89.1) | 0 | 9 (12.5) | 0.197 | |
| Laboratory data | |||||
| White blood cell count (cells/mm3) | 13,281 ± 8740 | 13,353 ± 6687 | 13,261 ± 9271 | 0.967 | |
| Hemoglobin (g/dL) | 10.1 ± 2.1 | 9.8 ± 2.4 | 10.1 ± 2.1 | 0.585 | |
| Platelet count (×1000 cells/mm3) | 228,570 ± 131,056 | 216,550 ± 157,332 | 231,900 ± 123,846 | 0.69 | |
| Serum creatinine (mg/dL) | 1.8 ± 1.7 | 1.6 ± 1.3 | 1.9 ± 1.8 | 0.584 | |
| Empirical antimicrobial therapy | |||||
| β-lactams | 41 (44.6) | 11 (55) | 30 (41.7) | 1.71 (0.63–4.64) | 0.289 |
| β-lactam/lactamase inhibitors | 20 (21.7) | 4 (20) | 16 (22.2) | 0.88 (0.26–2.99) | 0.999 |
| Ciprofloxacin | 10 (10.9) | 1 (5) | 9 (12.5) | 0.37 (0.04–3.1) | 0.685 |
| Levofloxacin | 24 (26.1) | 1 (5) | 23 (31.9) | 0.11 (0.01–0.89) | 0.015 |
| Carbapenems | 17 (18.5) | 4 (20) | 13 (18.1) | 1.14 (0.33–3.96) | 0.999 |
| Aminoglycosides | 9 (9.8) | 3 (15) | 6 (8.3) | 1.94 (0.44–8.57) | 0.402 |
| Tigecycline | 8 (8.7) | 2 (10) | 6 (8.3) | 1.22 (0.23–6.58) | 0.999 |
| Colistin | 6 (6.5) | 1 (5) | 5 (6.9) | 0.71 (0.08–6.41) | 0.999 |
| Inappropriate empirical antimicrobial therapy | 74 (80.4) | 20 (100) | 54 (75) | 0.01 | |
| Shock | 42 (45.7) | 9 (45) | 33 (45.8) | 0.97 (0.36–2.62) | 0.999 |
| Admission to intensive care unit | 44 (47.8) | 9 (45) | 35 (48.6) | 0.87 (0.32–2.34) | 0.775 |
| Case fatality | 25 (27.2) | 6 (30) | 19 (26.4) | 1.2 (0.4–3.56) | 0.748 |
Abbreviations: OR, odds ratio; CI, confidence interval.
should be replaced with the following:
The authors apologize for any inconvenience caused to the readers by these changes.
Reference
- 1.Lin J.-N., Lai C.-H., Yang C.-H., Huang Y.-H. Comparison of clinical manifestations, antimicrobial susceptibility patterns, and mutations of fluoroquinolone target genes between Elizabethkingia meningoseptica and Elizabethkingia anophelis isolated in Taiwan. J. Clin. Med. 2018;7:538. doi: 10.3390/jcm7120538. [DOI] [PMC free article] [PubMed] [Google Scholar]